The International Myeloma Foundations Says Newly Published Study Confirms Survival Advantage with Revlimid® and Further Advantages With Continous Use in Newly Diagnosed Multiple Myeloma Patients Not Eligible for Transplant

--Publication in the New England Journal of Medicine Follows Presentation Highlighted at ASH 2013--   --Supports US and European Approval of REVLIMID in New Diagnosed Multiple Myeloma--
Source: International Myeloma Foundation - Category: Hematology Source Type: news